Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 22;37(4):1077-1085.
doi: 10.1002/joa3.12586. eCollection 2021 Aug.

Cost-effectiveness of insertable cardiac monitors for diagnosis of atrial fibrillation in cryptogenic stroke in Australia

Vincent Thijs  1 , Klaus K Witte  2 , Carmel Guarnieri  3 , Koji Makino  3 , Dominic Tilden  3 , John Gillespie  4 , Marianne Huynh  4
Affiliations

Cost-effectiveness of insertable cardiac monitors for diagnosis of atrial fibrillation in cryptogenic stroke in Australia

Vincent Thijs et al. J Arrhythm. .

Abstract

Introduction: Detection of atrial fibrillation (AF) is required to initiate oral anticoagulation (OAC) after cryptogenic stroke (CS). However, paroxysmal AF can be difficult to diagnose with short term cardiac monitoring. Taking an Australian payer perspective, we evaluated whether long-term continuous monitoring for 3 years with an insertable cardiac monitor (ICM) is cost-effective for preventing recurrent stroke in patients with CS.

Methods: A lifetime Markov model was developed to simulate the follow-up of patients, comparing long-term continuous monitoring with an ICM to monitoring by conventional care. We used a linked evidence approach to estimate the rates of recurrent stroke when AF detection leads to initiation of OAC, as detected using ICM during the lifetime of the device or as detected using usual care. All diagnostic and patient management costs were modeled. Other model inputs were determined by literature review. Probabilistic sensitivity analysis (PSA) was undertaken to explore the effect of parameter uncertainty according to CHADS2 score and OAC treatment effect.

Results: In the base-case analysis, the model predicted an incremental cost-effectiveness ratio (ICER) of A$29 570 per quality-adjusted life year (QALY). Among CHADS2 subgroups analyses, the ICER ranged from A$26 342/QALY (CHADS2 = 6) to A$42 967/QALY (CHADS2 = 2). PSA suggested that the probabilities of ICM strategy being cost-effective were 53.4% and 78.7%, at thresholds of $30 000 (highly cost-effective) and $50 000 per QALY (cost-effective), respectively.

Conclusions: Long-term continuous monitoring with an ICM is a cost-effective intervention to prevent recurrent stroke in patients following CS in the Australian context.

Keywords: atrial fibrillation; cost‐effectiveness; cryptogenic stroke; insertable cardiac monitor; oral anticoagulation.

PubMed Disclaimer

Conflict of interest statement

Vincent Thijs has received modest speaker fees from Medtronic not connected with his work on this analysis; Klaus K. Witte has received modest consulting fees from Medtronic for his work on the economic analysis; this was work was based on but not with regards to this adaptation; Carmel Guarnieri, Koji Makino, and Dominic Tilden are employed by THEMA Consulting that received financial support from Medtronic Australasia to conduct the analysis and prepare the MSAC submission. Marianne Huynh is a Medtronic employee and stakeholder. John Gillespie was a Medtronic employee at the time of this analysis.

Figures

FIGURE 1
FIGURE 1
Model schematic of the current economic model. AF, atrial fibrillation; HS, hemorrhagic stroke; ICH, intracranial hemorrhage; IS, ischemic stroke; MB, major bleed; OAC, oral anticoagulant
See this image and copyright information in PMC

References

    1. Stroke Foundation. 2018. Top 10 facts about stroke. https://strokefoundation.org.au/About‐Stroke/Facts‐and‐figures‐about‐stroke. Accessed 2 Apr 2018.
    1. Andrade JG, Field T, Khairy P. Detection of occult atrial fibrillation in patients with embolic stroke of uncertain source: a work in progress. Front Physiol. 2015;6:100. 10.3389/fphys.2015.00100 - DOI - PMC - PubMed
    1. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382–90. - PubMed
    1. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population‐based study of incidence and risk factors. Stroke. 1999;30:2513–6. - PubMed
    1. Kolominsky‐Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long‐term survival in ischemic stroke subtypes: a population‐based study. Stroke. 2001;32:2735–40. - PubMed